Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $22.60.
Several brokerages recently weighed in on KURA. BidaskClub raised Kura Oncology from a “buy” rating to a “strong-buy” rating in a research note on Thursday. ValuEngine cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Wedbush began coverage on Kura Oncology in a research note on Tuesday, December 26th. They issued a “buy” rating and a $19.00 price target on the stock. Zacks Investment Research raised Kura Oncology from a “sell” rating to a “hold” rating in a research note on Thursday, February 8th. Finally, Oppenheimer set a $18.00 price target on Kura Oncology and gave the stock a “buy” rating in a research note on Thursday, November 16th.
A number of hedge funds have recently modified their holdings of KURA. Candriam Luxembourg S.C.A. purchased a new stake in shares of Kura Oncology in the third quarter worth $8,073,000. BlackRock Inc. grew its stake in shares of Kura Oncology by 49.1% in the fourth quarter. BlackRock Inc. now owns 1,524,817 shares of the company’s stock worth $23,331,000 after acquiring an additional 502,296 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of Kura Oncology in the third quarter worth $2,884,000. Nexthera Capital LP grew its stake in shares of Kura Oncology by 72.3% in the fourth quarter. Nexthera Capital LP now owns 445,550 shares of the company’s stock worth $6,817,000 after acquiring an additional 187,034 shares during the last quarter. Finally, State Street Corp purchased a new stake in shares of Kura Oncology in the second quarter worth $1,394,000. 62.83% of the stock is currently owned by institutional investors.
Shares of Kura Oncology (NASDAQ:KURA) opened at $22.15 on Friday. The firm has a market capitalization of $670.78, a price-to-earnings ratio of -14.29 and a beta of 4.94. Kura Oncology has a 12 month low of $5.90 and a 12 month high of $24.02. The company has a quick ratio of 13.48, a current ratio of 13.48 and a debt-to-equity ratio of 0.07.
COPYRIGHT VIOLATION WARNING: “Kura Oncology, Inc. (KURA) Receives Average Recommendation of “Buy” from Brokerages” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/23/kura-oncology-inc-kura-receives-average-recommendation-of-buy-from-brokerages.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.